Format

Send to

Choose Destination
Cancer. 2016 Jul 15;122(14):2186-96. doi: 10.1002/cncr.30039. Epub 2016 May 3.

The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia.

Author information

1
Department of Infectious Disease, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas.
2
The Alkek Center for Metagenomics and Microbiome Research, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas.
3
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
4
Department of Statistics, Rice University, Houston, Texas.
5
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
6
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
7
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
8
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

BACKGROUND:

Despite increasing data on the impact of the microbiome on cancer, the dynamics and role of the microbiome in infection during therapy for acute myelogenous leukemia (AML) are unknown. Therefore, the authors sought to determine correlations between microbiome composition and infectious outcomes in patients with AML who were receiving induction chemotherapy (IC).

METHODS:

Buccal and fecal specimens (478 samples) were collected twice weekly from 34 patients with AML who were undergoing IC. Oral and stool microbiomes were characterized by 16S ribosomal RNA V4 sequencing using an Illumina MiSeq system. Microbial diversity and genera composition were associated with clinical outcomes.

RESULTS:

Baseline stool α-diversity was significantly lower in patients who developed infections during IC compared with those who did not (P = .047). Significant decreases in both oral and stool microbial α-diversity were observed over the course of IC, with a linear correlation between α-diversity change at the 2 sites (P = .02). Loss of both oral and stool α-diversity was associated significantly with the receipt of a carbapenem P < 0.001. Domination events by the majority of genera were transient (median duration, 1 sample), whereas the number of domination events by pathogenic genera increased significantly over the course of IC (P = .002). Moreover, patients who lost microbial diversity over the course of IC were significantly more likely to contract a microbiologically documented infection within the 90 days after IC neutrophil recovery (P = .04).

CONCLUSIONS:

The current data present the largest longitudinal analyses to date of oral and stool microbiomes in patients with AML and suggest that microbiome measurements could assist with the mitigation of infectious complications of AML therapy. Cancer 2016;122:2186-96. © 2016 American Cancer Society.

KEYWORDS:

acute myeloid leukemia; gastrointestinal; induction chemotherapy; infectious complications; microbiome

PMID:
27142181
PMCID:
PMC5574182
DOI:
10.1002/cncr.30039
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center